Home » Stromedix Sets Sight on Trial for Pulmonary Fibrosis
Stromedix Sets Sight on Trial for Pulmonary Fibrosis
Cambridge, MA-based Stromedix is planning to begin a mid-stage trial of its lead drug in patients with a chronic lung disease called idiopathic pulmonary fibrosis before the end of June, CEO Michael Gilman said.
Xconomy
Xconomy
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May